Abstracts tagged "calcinosis"

Abstract Number: 2369 • 2015 ACR/ARHP Annual Meeting
Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: A Longitudinal Analysis
Matthew Lewis¹, Shufeng Li¹, Lorinda Chung² and David Fiorentino¹, ¹Dermatology, Stanford University, Stanford, CA, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Dermatomyositis (DM) patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are at increased risk of developing interstitial lung disease (ILD). The natural history of…
Abstract Number: 2960 • 2015 ACR/ARHP Annual Meeting
Sodium Thiosulfate in Calcinosis
Eliza Pelrine¹, Jessica K. Gordon², Murray Baron³ and Robert F. Spiera², ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Calcinosis occurs in ~25% of patients with Systemic Sclerosis (SSc) and causes pain, morbidity, and decreased quality of life. The treatment of calcinosis is…
Abstract Number: 830 • 2015 ACR/ARHP Annual Meeting
Calcinosis Is Associated with Digital Ulcers and Osteoporosis in Patients with Systemic Sclerosis
Antonia Valenzuela¹, Murray Baron², Ariane L. Herrick³, Susana Proudman⁴, Wendy Stevens⁵, Tatiana Sofia Rodriguez-Reyna⁶, Alessandra Vacca⁷, Thomas A. Medsger Jr.⁸, Monique Hinchcliff⁹, Vivien Hsu¹⁰, David Fiorentino¹¹, Lorinda Chung¹² and the Canadian Scleroderma Research Group, and the ASIG rubric, ¹Stanford University School of Medicine, Stanford, CA, ²Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴Rheumatology Unit, Royal Adelaide Hospital North Terrace, Adelaide, Australia, ⁵Department of Rheumatology, St. Vincent’s Hospital Melbourne, Melbourne, Australia, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷University Hospital of Cagliari, Rheumatology Unit, Monserrato, Italy, ⁸Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology, Northwestern University, Chicago, IL, ¹⁰Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ¹¹Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ¹²Stanford University, Palo Alto, CA
Background/Purpose: Calcinosis is a debilitating complication of systemic sclerosis (SSc). We sought to determine the clinical factors associated with calcinosis in an international multi-center collaborative…
Abstract Number: 1898 • 2015 ACR/ARHP Annual Meeting
Are There Risk Factors for Calcinosis in Scleroderma?
Sneha Pai¹ and Vivien Hsu², ¹Rheumatology, Robert Wood Johnson Medical School Hospital, New Brunswick, NJ, ²Medicine, Rutgers University, New Brunswick, NJ
Background/Purpose: Calcinosis is the deposition of calcium hydroxyapatite in the soft tissues in patients with scleroderma spectrum disorders (SSc). Risk factors are unknown and there…
Abstract Number: 1904 • 2015 ACR/ARHP Annual Meeting
Development of the Mawdsley Calcinosis Questionnaire (MCQ) Version 1 – a Patient-Reported Outcome Measure (PROM) for Systemic Sclerosis Related Calcinosis (SSc-Ca)
Lesley Ann Saketkoo¹, Kim Fligelstone², Evan Busman³, Angela Christensen⁴, Sophia Cenac⁵, Samara Khalique⁶, Andrew Aubin⁷, Veronika K. Jaeger⁸, Anne Mawdsley⁹, Jessica K. Gordon¹⁰, Randi Kaufman¹¹, Murray Baron¹², Virginia D. Steen¹³ and Tracy M. Frech¹⁴, ¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ³Atlanta Scleroderma Support Group, Atlanta, GA, ⁴Tulane University School of Medicine, New Orleans, LA, ⁵Louisiana State University Health Science Center, New Orleans, LA, ⁶Louisiana State University Health Sciences Center, New Orleans, LA, ⁷Louisiana State University School of Medicine, New Orleans, LA, ⁸Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ⁹Raynaud's & Scleroderma - Care and Support UK, Cheshire, United Kingdom, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Lousiana State University Health Sciences Center - School of Public Health, New Orleans, LA, ¹²Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ¹³Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁴Div of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: SSc-Ca is a poorly understood vascular complication of SSc that usually related to extreme constant pain and infection/amputation risk for persons living with SSc-Ca…
Abstract Number: 2707 • 2014 ACR/ARHP Annual Meeting
Systemic Sclerosis Related Calcinosis: Patients Provide What Specialists Want to Learn
Angela Christensen¹, Samara Khalique², Sophia Cenac³, Kim Fligelstone⁴, Anne Mawdsley⁵, Tracy Frech⁶, Jessica K. Gordon⁷, Murray Baron⁸, Evan Busman⁹, Virginia D. Steen¹⁰ and Lesley Ann Saketkoo¹¹, ¹Tulane University School of Medicine, New Orleans, LA, ²Louisiana State University Health Sciences Center, New Orleans, LA, ³Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Raynaud's & Scleroderma - Care and Support UK, Cheshire, United Kingdom, ⁶Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Pavillion A, Rm 216, Jewish General Hospital, Montreal, QC, Canada, ⁹Atlanta Scleroderma Support Group, Atlanta, GA, ¹⁰Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ¹¹Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Calcinosis is a disabling, rarely discussed manifestation of SSc for which the natural history and management is poorly understood. Last year, the Scleroderma Clinical…
Abstract Number: 2191 • 2014 ACR/ARHP Annual Meeting
Intravenous Sodium Thiosulfate for Treatment of Refractory Calcinosis in Rheumatic Disease
Ross Thibodaux¹, Bahnsen Miller¹ and Stephen Lindsey^2,3, ¹Internal Medicine, Louisiana State University Health Science Center, Baton Rouge, LA, ²Chief Div of Rheumatology, Ochsner Clinic Baton Rouge, Baton Rouge, LA, ³Internal Medicine - Rheumatology, Louisiana State University Health Science Center, Baton Rouge, LA
Background/Purpose: Calcinosis, or dystrophic calcification, is a poorly understood, debilitating condition commonly manifested in connective tissue diseases such as scleroderma and polymyositis. Despite treatment of…
Abstract Number: 1926 • 2014 ACR/ARHP Annual Meeting
Nailfold Videocapillaroscopy Patterns Associated with Calcinosis and Acro-Osteolysis in Systemic Sclerosis
Jerome Avouac¹, Laetitia Morardet², Maya Sammour³, Andre Kahan², Antoine Feydy³ and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ³Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France
Background/Purpose: Calcinosis and acro-osteolysis are frequent in systemic sclerosis (SSc). They may be related to digital vasculopathy, which can be assessed by nailfold videocapillaroscopy (NVC).…
Abstract Number: 1315 • 2014 ACR/ARHP Annual Meeting
Cross-Sectional Evaluation of Hydroxychloroquine (HCQ) Therapy in Children with Juvenile Dermatomyositis (JDM) Enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Yonit Sterba¹, Dawn Wahezi² and For the CARRA investigators³, ¹Pediatric Rheumatology, Montefiore Medical Center, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Duke Children's Hospital, Durham, NC
Background/Purpose: Hydroxychloroquine is an antimalarial agent commonly used in the treatment of rheumatologic diseases. Data on the use of HCQ in JDM is limited, primarily…
Abstract Number: 2086 • 2013 ACR/ARHP Annual Meeting
Defining The Prevalence and Associated Risk Factors For Calcinosis In Adult Dermatomyositis Patients
Jessie Werner¹, Jason Liebowitz², Andrew L. Mammen³ and Lisa Christopher-Stine⁴, ¹Medicine, University of Maryland School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³NIAMS, NIH, Bethesda, MD, ⁴Medicine and Neurology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Calcinosis is known to be associated with junvenile dermatomyositis, but the prevalence and risk factors associated with the development of calcinosis in adult dermatomyositis…
Abstract Number: 679 • 2013 ACR/ARHP Annual Meeting
Validation Of a Novel Radiographic Scoring System For Calcinosis Affecting The Hands Of Patients With Systemic Sclerosis
Lorinda Chung¹, Antonia Maria Valenzuela Vergara², David Fiorentino³, Kate Stevens², Shufeng Li⁴, Jonathan Harris⁵, Charles E. Hutchinson⁶, Shervin Assassi⁷, Lorenzo Beretta⁸, Santhanam Lakshminarayanan⁹, Tatiana Rodriguez Reyna¹⁰, Christopher P. Denton¹¹, Rebecca G. Taillefer¹², Solene Tatibouet¹³, Ariane Herrick¹⁴ and Murray Baron¹⁵, ¹Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ²Stanford University School of Medicine, Stanford, CA, ³Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Dermatology, Stanford University School of Medicine, Palo Alto, CA, ⁵Salford Royal Hospital, Manchester, United Kingdom, ⁶Warwick Medical School, University of Warwick, Coventry, United Kingdom, ⁷Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁸Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁹Dept of Med/Div Rheum Diseases, University of Connecticut School of Medicine, Farmington, CT, ¹⁰Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ¹¹Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ¹²University of Montreal, Montreal, QC, Canada, ¹³Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹⁴Musculoskeletal Research Group, University of Manchester, Salford, United Kingdom, ¹⁵Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Calcinosis affects approximately 25% of patients with systemic sclerosis (SSc) and is associated with substantial morbidity. There are currently no validated outcome measures…
Abstract Number: 228 • 2013 ACR/ARHP Annual Meeting
The Composition and Structure Of Calcifications In Juvenile Dermatomyositis Differs From Calcified Aortic Valves Removed From Adults Without JDM
Lauren M. Pachman^1,2, Gabrielle A. Morgan¹, Patrick M. McCarthy³, Anna Huskin³, S. Chris Malaisrie³, Lyudmila Spevak⁴, Stephen Doty⁴ and Adele Boskey⁴, ¹Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, ²Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute, Chicago, IL, ⁴Hospital for Special Surgery, New York, NY
Background/Purpose: Juvenile Dermatomyositis (JDM) is a systemic vasculopathy, primarily involving the micro vasculature. Soft tissue calcification occurs in 15-30% of cases, and is associated with…
Abstract Number: 229 • 2012 ACR/ARHP Annual Meeting
Clinical Differences Between Adult and Juvenile Dermatomyositis Associated with Anti-NXP2 Autoantibodies
Sarah Tansley¹, Zoe Betteridge¹, Harsha Gunawardena², Lucy R. Wedderburn³, Hector Chinoy⁴, Robert G. Cooper⁵, Jiri Vencovsky⁶, Lenka Plestilova⁷, Ingrid E. Lundberg⁸, Katalin Danko⁹, Melinda Vincze¹⁰, Neil McHugh¹¹, UK JDRG¹² and EuMyoNet¹³, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Rheumatology, North Bristol NHS Trust, Bristol, United Kingdom, ³Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ⁴Rheumatology, The University of Manchester, Manchester, United Kingdom, ⁵Rheumatic Diseaes Center, Salford Royal Foundation Trust, Salford, United Kingdom, ⁶Institute of Rheumatology, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague 2, Czech Republic, ⁸Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁹University of Debrecen, University of Debrecen, Debrecan, Hungary, ¹⁰University of Debrecen, University of Debrecen, Debrecen, Hungary, Debrecan, Hungary, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹²Institute of Child Health, London, United Kingdom, ¹³Rheumatology Unit, Stockholm, Sweden
Background/Purpose: Myositis specific antibodies (MSA) can divide dermatomyositis patients into distinct clinical subsets and help predict the risk of disease complications such as interstitial lung…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].